Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis

Clinical Transplantation

Volumn 25, Issue 3, 2011, Pages

  Skagen, Catherine L ^a   Jou, Janice H ^a   Said, Adnan ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

de novo hepatitis; Hepatitis B; Hepatitis B core antibody positive donor; Liver transplantation; Outcomes

Indexed keywords

ADEFOVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; LAMIVUDINE;

ARTICLE; DE NOVO HEPATITIS B; GRAFT RECIPIENT; HEPATITIS B; HUMAN; IMMUNE STATUS; INFECTION RATE; LIVER GRAFT; ORGAN DONOR; PRIORITY JOURNAL; PROPHYLAXIS; RISK; SYSTEMATIC REVIEW;

HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HUMANS; LIVER TRANSPLANTATION; LIVING DONORS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; REVIEW LITERATURE AS TOPIC; RISK FACTORS; SURVIVAL RATE;

EID: 79958714454     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01409.x     Document Type: Article

References (42)

1. Renz JF, Kin C, Kinkhabwala M et al. Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann Surg 2005: 242: 556;discussion 563-5.
2. Dickson RC, Everhart JE, Lake JR et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997: 113: 1668.
3. Munoz SJ. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002: 8(10 Suppl 1): S82.
4. Lee KW, Lee DS, Lee HH et al. Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation. Transplant Proc 2004: 36: 2311.
5. Barcena R, Moraleda G, Moreno J et al. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers. World J Gastroenterol 2006: 12: 2070.
6. Castells L, Vargas V, Rodriguez-Frias F et al. Transmission of hepatitis B virus by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Transplant Proc 1999: 31: 2464.
7. Chen YS, Wang CC, De Villa VH et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002: 16: 405.
8. De Feo TM, Poli F, Mozzi F et al. Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study. Transplant Proc 2005: 37: 1238.
9. Dodson SF, Bonham CA, Geller DA et al. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999: 68: 1058.
10. Dodson SF, Issa S, Araya V et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997: 64: 1582.
11. Donataccio D, Roggen F, De Reyck C et al. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool. Transpl Int 2006: 19: 38.
12. Douglas DD, Rakela J, Wright TL et al. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997: 3: 105.
13. Fabrega E, Garcia-Suarez C, Guerra A et al. Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transpl 2003: 9: 916.
14. Holt D, Thomas R, Van Thiel D et al. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002: 137: 572;discussion 575-6.
15. Celebi Kobak A, Karasu Z, Kilic M et al. Living donor liver transplantation from hepatitis B core antibody positive donors. Transplant Proc 2007: 39: 1488.
16. Kwon CH, Suh KS, Cho JY et al. Change of hepatitis B virus DNA status in anti-HBc positive liver graft. Korean J Hepatol 2006: 12: 191.
17. Loss GE Jr, Mason AL, Nair S et al. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors? Liver Transpl 2003: 9: 1258.
18. Manzarbeitia C, Reich DJ, Ortiz JA et al. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002: 8: 556.
19. Nery JR, Nery-Avila C, Reddy KR et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003: 75: 1179.
20. Prakoso E, Strasser SI, Koorey DJ et al. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors. Clin Transplant 2006: 20: 369.
21. Prieto M, Gomez MD, Berenguer M et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001: 7: 51.
22. Rokuhara A, Tanaka E, Yagi S et al. De novo infection of hepatitis B virus in patients with orthotopic liver transplantation: analysis by determining complete sequence of the genome. J Med Virol 2000: 62: 471.
23. Roque-Afonso AM, Feray C, Samuel D et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002: 50: 95.
24. Suehiro T, Shimada M, Kishikawa K et al. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Int 2005: 25: 1169.
25. Takemura N, Sugawara Y, Tamura S et al. Liver transplantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience. Dig Dis Sci 2007: 52: 2472.
26. Uemoto S, Sugiyama K, Marusawa H et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998: 65: 494.
27. Wachs ME, Amend WJ, Ascher NL et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995: 59: 230.
28. Yu AS, Vierling JM, Colquhoun SD et al. Transmission of hepatitis B infection from hepatitis B core antibody - positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001: 7: 513.
29. Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programs. Liver Transpl 2009: 15: 223.
30. Michalak TI, Pasquinelli C, Guilhot S et al. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994: 93: 230.
31. Cabrerizo M, Bartolome J, De Sequera P et al. Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff. J Am Soc Nephrol 1997: 8: 1443.
32. Onozawa M, Hashino S, Izumiyama K et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005: 79: 616.
33. Kaloyannidis P, Batsis I, Yannaki E et al. Allografted recipients immunized against hepatitis B virus are at high risk of gradual surface antibody (HbsAb) disappearance post transplant, regardless of adoptive immunity transfer. Biol Blood Marrow Transplant 2007: 13: 1049.
34. Abdelmalek MF, Pasha TM, Zein NN et al. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. Liver Transpl 2003: 9: 1253.
35. Su WJ, Ho MC, Ni YH et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr 2009: 48: 203.
36. Zerbini A, Pilli M, Boni C et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008: 134: 1470.
37. Vento S, Di Perri G, Luzzati R et al. Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS. Lancet 1989: 1: 332.
38. Nagington J. Reactivation of hepatitis b after transplantation operations. Lancet 1977: 1: 558.
39. Iwai K, Tashima M, Itoh M et al. Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period. Bone Marrow Transplant 2000: 25: 105.
40. Dhedin N, Douvin C, Kuentz M et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998: 66: 616.
41. Gish RG. Hepatitis B treatment: current best practices, avoiding resistance. Cleve Clin J Med 2009: 76(Suppl 3): S14.
42. Veenstra DL, Sullivan SD, Clarke L et al. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2007: 25: 963.